Economic value of gemcitabine compared to cisplatin and etoposide in non-small cell lung cancer

Lung Cancer

Volumn 14, Issue 1, 1996, Pages 45-61

  Copley Merriman, Catherine ^a,b   Corral, Javier ^a   King, Kimberly ^a   Whiteside, Robert ^a   Voi, Maurizio ^a   Dorr, F Andrew ^a   McDonald, Robert C ^a  

^a ELI LILLY AND COMPANY   (United States)

^b PFIZER INC   (United States)

Author keywords

Cisplatin; Etoposide; Gemcitabine; Health economics; Lung cancer; Non small cell

Indexed keywords

CISPLATIN; ETOPOSIDE; GEMCITABINE;

ANEMIA; ARTICLE; CONTROLLED STUDY; ECONOMIC ASPECT; EDEMA; HUMAN; INFLUENZA; LUNG NON SMALL CELL CANCER; MODEL; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; THROMBOCYTOPENIA; VOMITING;

EID: 0030000615     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/0169-5002(95)00540-4     Document Type: Article

References (35)

1. Ginsberg RJ, Kris MG, Armstrong JG. Cancer of the Lung. In: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer: Principles and Practice of Oncology, Fourth Edition, JB Lippincott & Co., Philadelphia, 1993; 673-723.
2. Ihde DC. Chemotherapy of Lung Cancer. N Engl J Med 1992; 327: 1434-1441.
3. Smith IE. Palliative chemotherapy for advanced non-small cell lung cancer. Br Med J 1994; 308: 429-430.
4. Evans WK. Rationale for the treatment of non-small cell lung cancer. Lung Cancer 1993; 9 (Suppl 2): S5-S14.
5. Gatzemeier U, Shepherd F, Le Chevalier T, et al. A multicenter phase II trial with gemcitabine in non-small cell lung cancer (NSCLC). Lung Cancer 1994; 11 (Suppl 1): 121 (abstr 461).
6. Chang AY, Kim K, Glick J, et al. Phase II study of Taxol, merbarone, and piroxantrone in stage IV non-small cell lung cancer: The Eastern Cooperative Oncology Group Results. J Natl Cancer Inst 1993; 85: 388-394.
7. Murphy WK, Fosella FV, Winn RJ, et al. Phase II study of taxol in patients with untreated advanced non-small cell lung cancer. J Natl Cancer Inst 1993; 85: 384-388.
8. Depierre A, Lemarie E, Dabouis G, et al. A phase II study of Navelbine (vinorelbine) in the treatment of non-small cell lung cancer. Am J Clin Oncol (CCT) 1991; 14: 115-119.
9. Fernandez O, Bruno J, Mickiewicz E, et al. Randomized comparison of navelbine (NVB) and cisplatin (CDDP) versus navelbine alone in patients with inoperable non-small cell lung cancer (NSCLC). Proc 15th Int Cancer Congr J Cancer Res Clin Oncol V 116 Suppl, 1990.
10. Le Chevalier T, Brisgand D, Douillard JY, et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: Results of a European multicenter trial including 612 patients. J Clin Oncol 1994; 12: 360-367.
11. Souhami RL, Rudd RM, Spiro SG, et al. Phase II study of edatrexate in stage III and IV non-small cell lung cancer. Cancer Chemother Pharmacol 1992; 30: 465-468.
12. Lee JS, Libshitz HI, Murphy WK, et al. Phase II study of 10-ethyl-10-deaza-aminopterin (10EdAM; CGP 30 694) for stage IIIB or IV non-small cell lung cancer. Invest New Drugs 1990; 8: 299-304.
13. Shum KY, Kris MG, Gralla RJ, et al. Phase II study of 10-ethyl-10-deaza-aminopterin in patients with stage III and IV non-small cell lung cancer. J Clin Oncol 1988; 6: 446-450.
14. Fukuoka M, Niitani H, Suzuki A, et al. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small cell lung cancer. J Clin Oncol 1992; 10: 16-20.
15. Feigal EG, Christian M, Cheson B, Grever M, Friedman MA. New chemotherapeutic agents in non-small cell lung cancer. Sem Oncol 1993; 20: 185-201.
16. Smith TJ, Hillner BE, Desch CE. Commentary-efficacy and cost-effectiveness of cancer treatment. Rational allocation of resources based on decision analysis. J Natl Cancer Inst 1993; 85: 1460-1474.
17. Jaakkimainen L, Goodwin PJ, Pater J, Warde P, Murray N, Rapp E. Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial in non-small cell lung cancer. J Clin Oncol 1990; 8: 1301-1309.
18. Brandabur J, Kozarek R, Terrence B, Hofer B, Ryan J, Traverso W, Freeny P, Lewis G. Nonoperative vs. operative treatment of obstructive jaundice in pancreatic cancer: cost and survival analysis. Am J Gastroenterol 1988; 83: 1132-1139.
19. DMI Research Institute. Patient Chart Review, 1992.
20. Chalfin DB, Holbein ME, Fein AM, Carlon GC. Cost-effectiveness of monoclonal antibodies to gram-negative sepsis in ICU patients. JAMA 1993; 269: 249-254.
21. Gatzemeier U, Shepherd FA, Le Chevalier T, Weynants P, Cottier B, Groen HJM, et al. Activity of gemcitabine in patients with non-small cell lung cancer: A multicenter extended phase II study. Eur J Cancer 1996 (in press)
22. Sagmeister M, Gessner U, Horisberger B. Assessment of the costs of febrile neutropenia event in chemotherapy as a basis for socio-economic evaluations of new cancer treatments. Intl J Health Sciences 1991; 2: 179-185.
23. Calvert AH, Urie J. The costs of carboplatin treatment. Sem Oncol 1991; 18 (suppl 2): 28-31.
24. Durivage HJ, Burnham NL. Prevention and management of toxicities associated with antineoplastic drugs. J Pharm Prac 1991; 4: 27-48.
25. Forbes JM, Anderson MD, Anderson GF, Bleecker GC, Rossi EC, Moss GS. Blood transfusion costs: a multicentre study. Transfusion 1991; 31: 318-323.
26. Glaspy JA, Bleecker GC, Crawford J, et al. The impact of therapy with recombinant granulocyte colony-stimulating factor (GCSF) on the health care cost associated with cancer chemotherapy. Blood 1991; 78 (suppl 10): 7a (abstr 20).
27. Lyman GH, Lyman CG, Sanderson RA, Balducci L. Decision analysis of hematopoetic growth factor use in patients receiving cancer chemotherapy. J Natl Cancer Inst 1993; 85: 488-493.
28. Indiana Community Cancer Care, November 1993 billing data.
29. Graham P, Boyages J. Economic and quality of life aspects of treating small cell lung cancer. Pharmaco Economics 1993; 3: 446-453.
30. Souadjian JV, Bhaskar B, Briscoe KE, Opfell RW, Agopian JM. Home chemotherapy (CT): safety and cost-effectiveness. Proc Am Soc Clin Oncol 1992; 11: 410 (abstr 1436).
31. Reed E. Platinum analogs. In: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer: Principles & Practice of Oncology, Fourth Edition, JB Lippincott & Co., Philadelphia, 1993; 390-399.
32. Donehower RC, Rowinsky EK. Anticancer drugs derived from plants. In: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer: Principles & Practice of Oncology, Fourth Edition, JB Lippincott & Co., Philadelphia, 1993; 409-417.
33. Perry MC. Toxicity: ten years later. Sem Oncol 1992; 19: 453-457.
34. Whittington R, Goa K. Idarubicin: A pharmacoeconomic evaluation of its use in adult patients with acute myeloid leukemia. Pharmaco Economics 1993; 4: 287-307.
35. Thatcher N, Anderson H, Betticher DC, Ranson M. Symptomatic benefit from gemcitabine and other chemotherapy in advanced non-small cell lung cancer: changes in performance status and tumour-related symptoms. Anti-Cancer Drugs 1995; 6 (suppl 6): 39-48.